Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 45674E109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
| William Tai-Wei Ho 13G/A | 5.6% |
2/14/2025
Event 12/31/2024
|
||
|
Orin Hirschman
13G/A
|
4.4% |
7/29/2025
Event 6/30/2025
|
||
| Orin Hirschman | 4.4% | |||
| AIGH Capital Management LLC | 0% | |||
|
BIOS Fund II, LP
13D/A
|
4.0% |
12/29/2025
Event 12/22/2025
|
||
| BIOS Fund II, LP | 0.2% | |||
| BIOS Fund II QP, LP | 0.6% | |||
| BIOS Fund II NT, LP | 0.1% | |||
| BIOS Incysus Co-Invest I, LP | 0.3% | |||
| BIOS Fund III, LP | 0.2% | |||
| BIOS Fund III QP, LP | 1.3% | |||
| BIOS Fund III NT, LP | 0.2% | |||
| Bios Clinical Opportunity Fund, LP | 1.1% | |||
| BP Directors, LP | 0% | |||
| Bios Equity Partners, LP | 0% | |||
| Bios Equity Partners II, LP | 1.3% | |||
| BIOS Equity Partners III, LP | 1.7% | |||
| Bios Equity COF, LP | 1.1% | |||
| Cavu Management, LP | 2.9% | |||
| BIOS Capital Management, LP | 4.0% | |||
| Cavu Advisors, LLC | 2.9% | |||
| BIOS Advisors GP, LLC | 4.0% | |||
| Kreis Leslie W. | 2.9% | |||
| Fletcher Aaron G.L. | 4.0% | |||
|
Alyeska Investment Group, L.P.
13G/A
|
2.6% |
8/14/2025
Event 6/30/2025
|
||
| Alyeska Investment Group, L.P. | 2.6% | |||
| Alyeska Fund GP, LLC | 2.6% | |||
| Anand Parekh | 2.6% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 1 | 287 k | $622 k |
| 2025 Q2 | 1 | 287 k | $599 k |
| 2025 Q1 | 29 | 21.7 M | $3.60 M |
| 2024 Q4 | 27 | 30.0 M | $7.72 M |
| 2024 Q3 | 28 | 7.63 M | $2.06 M |
| 2024 Q2 | 28 | 7.74 M | $6.77 M |
| 2024 Q1 | 34 | 8.64 M | $10.2 M |
| 2023 Q4 | 33 | 8.58 M | $11.4 M |
| 2023 Q3 | 22 | 2.48 M | $2.58 M |
| 2023 Q2 | 23 | 2.33 M | $3.59 M |
| 2023 Q1 | 18 | 1.37 M | $1.78 M |
| 2022 Q4 | 17 | 1.21 M | $2.79 M |
| 2022 Q3 | 18 | 1.20 M | $2.42 M |
| 2022 Q2 | 16 | 2.36 M | $5.50 M |
| 2022 Q1 | 15 | 2.05 M | $7.02 M |
| 2021 Q4 | 15 | 1.78 M | $7.80 M |
| 2021 Q3 | 14 | 1.77 M | $12.2 M |